FOLH1 and prostate carcinoma: Another possible explanation to the low PSA response trends in the 177Lu-PSMA-617 therapy refractory group patients may be the down-regulation of PSMA expression in the prostate cancer cells seen as diffuse or low uptake on 68Ga-PSMA-PET/CT scan 20.